Chartwell Investment Partners
ESPR icon

Chartwell Investment Partners’s Esperion Therapeutics ESPR Stock Holding History

Chartwell Investment Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-27,418
Closed -$1.37M – 415
2017
Q3 		$1.37M Buy
+27,418
New +$1.32M 0.05% 358

Other funds holding ESPR

BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Chartwell Investment Partners's ESPR Position: Q4 2017 in Review

Chartwell Investment Partners sold out of Esperion Therapeutics (ESPR) in Q4 2017, closing a stake of 27,418 shares — an estimated $1.37M sold.

Chartwell Investment Partners first reported a position in ESPR in Q3 2017 and held it in 1 quarter. The position peaked at $1.37M in Q3 2017. 165 funds tracked by Wall St. Rank hold ESPR as of Q4 2017.

  • Chartwell Investment Partners reported no remaining Esperion Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Chartwell Investment Partners sold 27,418 Esperion Therapeutics shares in Q4 2017, an estimated $1.37M.
  • Chartwell Investment Partners first reported a position in Esperion Therapeutics in Q3 2017 and held it in 1 quarter.
  • Chartwell Investment Partners's Esperion Therapeutics position peaked at $1.37M in Q3 2017.
  • 165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2017.

Based on Chartwell Investment Partners's 13F filing for Q4 2017, filed 8 Feb 2018.